TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 421548
Drug: High-nicotine cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-nicotine cigarette (2.6 mg nicotine, 4.5 vol percent CO)
Study: 421548
Drug: Low-nicotine cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-nicotine cigarette (0.1 mg nicotine, 1.1 vol percent CO)
Study: 421548
Drug: Cigar (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigar (not inhaled)
Study: 421548
Drug: High-nicotine cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-nicotine cigarette after beta blocker
Study: 421548
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of CO
Study: 22070180
Drug: Medication-free subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free subjects with autism (n=77)
Study: 7565419
Drug: I.V. propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. propofol 2.5 mg/kg (G1, G3, G5)
Study: 7565419
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg/kg (G2, G4, G6)
Study: 465920
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium containing 53 mg iodine/kg body weight
Study: 465920
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium containing 75 mg iodine/kg body weight
Study: 465920
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium containing 106 mg iodine/kg body weight
Study: 465920
Drug: Infusion technique
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion technique over 3-8 hours
Study: 465920
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage regimen (106 mg and 150 mg iodine/kg)
Study: 25559090
Drug: Group-based memory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based memory rehabilitation programme (10 weekly sessions)
Study: 17512355
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day of statins
Study: 19778662
Drug: Statin therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapies
Study: 9676471
Drug: Oral tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tenoxicam 40 mg
Study: 7833497
Drug: Insulin at
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin at 5 microU/mL
Study: 7833497
Drug: Gliclazide treatment
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide treatment
Study: 21761263
Drug: Postexperimental inquiries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postexperimental inquiries (PEI) administered as a face-to-face interview
Study: 15965424
Drug: 12-week alefacept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week alefacept treatment
Study: 8067226
Drug: Heparin-coated equipment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated equipment (CBAS) with reduced i.v. heparin (1.5 mg.kg‐1)
Study: 8067226
Drug: Noncoated equipment
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noncoated equipment with full heparinization (3 mg.kg‐1)
Study: 27505301
Drug: Concomitant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant Therapy (CT) 14-day
Study: 25129681
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (2 mg/kg first dose, followed by 2 mg/kg/d in 2 divided doses for 3 days)
Study: 11709454
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment from a physiotherapist in primary care for 12 weeks
Study: 7943088
Drug: Double-dose dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Double-dose dexamethasone (10 mg intravenously every 12 hours until delivery)
Study: 31710864
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg/day
Study: 1450096
Drug: Disopyramide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (2 mg/kg body weight)
Study: 26865162
Drug: Acceptance Commitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance Commitment Therapy (up to eight sessions, each 1 hour)
Study: 26865162
Drug: Acceptance Commitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance Commitment Therapy
Study: 15996416
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied three times per week for 16 weeks
Study: 11923046
Drug: L-arginine (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (700 mg) administered four times daily during TD-GTN therapy
Study: 9811376
Drug: Capsaicin in
Normalized name: capsaicin in castor oil 0.035 % TOPICAL LIQUID (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin in candy formulation
Study: 7666103
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate 1,600 mg/d (n = 27)
Study: 2564949
Drug: recombinant pro-urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant pro-urokinase (rscu-PA) 80 mg (20 mg bolus followed by 60 mg infusion for 60 min)
Study: 401690
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN), mean dose 29 mg
Study: 10353581
Drug: Sublingual placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual placebo
Study: 20151522
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of rocuronium
Study: 20151522
Drug: Cumulative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative fractional doses of rocuronium
Study: 20151522
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of 400 microg-Kg(‐1) of rocuronium
Study: 10863856
Drug: Ribavirin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin 1,200 mg/day for 24 weeks
Study: 8922661
Drug: Sequential HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential HRT
Study: 1332094
Drug: MCPP (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCPP (0.35 mg/kg)
Study: 18082737
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate tablets
Study: 11406744
Drug: Serious adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serious adverse drug reactions observed by general practitioners
Study: 9003851
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at a dosage of 15 mg/kg per day, increased to 30 mg/kg per day if necessary
Study: 28468518
Drug: oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral morphine
Study: 26940689
Drug: transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: transdermal fentanyl
Study: 24712653
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of a standardized ginger extract per day (300 mg per capsule, administered q.i.d for five days during the first three cycles of chemotherapy)
Study: 24712653
Drug: Standard anti-emetic
Normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-emetic therapy (placebo)
Study: 22574741
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml apple juice
Study: 22574741
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol with 300 ml water
Study: 18794187
Drug: Internet‐based cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet‐based cognitive‐behavioral therapy (NET)
Study: 9313245
Drug: Somnium (lorazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somnium (lorazepam 1 mg plus diphenhydramine 25 mg)
Study: 28364943
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg)
Study: 8365305
Drug: ATIII (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATIII (90 to 120 IU/kg in loading dose, then 90 to 120 IU/kg/d during 4 days)
Study: 24089587
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) treatment
Study: 24669774
Drug: Dose to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to the ipsilateral masseter
Study: 21734980
Drug: Potassium oxalate‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium oxalate‐based desensitizing agent (BisBlock) with Adper Single Bond 2 adhesive
Study: 21734980
Drug: Adper Single
Normalized name: Asper-Flex
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adper Single Bond 2 adhesive without desensitizing agent
Study: 21734980
Drug: One‐Step adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: One‐Step adhesive with potassium oxalate‐based desensitizing agent (BisBlock)
Study: 21734980
Drug: One‐Step adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: One‐Step adhesive without desensitizing agent
Study: 22011421
Drug: Direct-to-smoker (DTS)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-to-smoker (DTS) outreach offering free tobacco treatment including up to 8 weeks of nicotine patches (NRT)
Study: 22011421
Drug: Direct-to-smoker (DTS)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-to-smoker (DTS) outreach offering free tobacco treatment
Study: 789436
Drug: Flunisolide (0.025%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (0.025% solution, two sprays in each nostril twice a day for 4 weeks)
Study: 11564390
Drug: Omapatrilat 25
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 25 mg and 50 mg
Study: 30811620
Drug: Microwave treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave treatment at maximum energy level (5.8 GHz/axilla)
Study: 26479510
Drug: Moderate neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate neuromuscular blockade (single bolus of rocuronium 0.3 mg kg with spontaneous recovery) and standard-pressure pneumoperitoneum (12 mmHg)
Study: 10337859
Drug: Mesterolone 100
Normalized name: mesterolone
DrugBank: Mesterolone (DB13587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesterolone 100 mg orally daily (MES)
Study: 10337859
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 160 mg orally daily (TU)
Study: 7202826
Drug: Indobufen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (3 single oral doses)
Study: 7202826
Drug: Indobufen (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (same dose)
Study: 7202826
Drug: Indobufen (increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (increasing doses)
Study: 22040521
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA, sodium valproate, 1000 mg once daily)
Study: 17449576
Drug: Psyllium (7.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (7.28 g) and plant sterols (2 g)
Study: 2719896
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg buccal morphine
Study: 835542
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid 500 mg
Study: 835542
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid 750 mg
Study: 835542
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg)
Study: 31136549
Drug: Red Spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Spinach Extract (RSE) 1 g daily for 7 days
Study: 27861932
Drug: Swallow therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallow therapy interventions
Study: 24195839
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture and Naproxen Sustained Release Tablets
Study: 11446878
Drug: Rabeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (10 mg b.i.d.) with amoxicillin (500 mg t.i.d.)
Study: 10209375
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam 20 mg
Study: 7600216
Drug: PUVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA therapy (8‐methoxypsoralen 0.6 mg/kg administered orally 2 hours before irradiation)
Study: 365428
Drug: Prazosin (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (17 mg) substituted for methyldopa
Study: 11767208
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) 20 g per day for 4 weeks
Study: 11767208
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) 20 g per day with vitamin E 200 mg per day for 3 weeks
Study: 11767208
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) 20 g per day for 3 weeks
Study: 9284857
Drug: Intravenous bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bumetanide 3.25 mg at 0 hours and again at 6 hours
Study: 9284857
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of bumetanide 0.5 mg/hr for 6 hours
Study: 9284857
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 0.5 mg bumetanide at 0 hours followed by a bolus regimen
Study: 31957130
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) session before procedure
Study: 31957130
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Music Therapy)
Study: 29999194
Drug: Muffins with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muffins with 20 g flaxseed
Study: 29999194
Drug: Muffins with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muffins with 30 g flaxseed
Study: 29999194
Drug: Muffins with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muffins with 0 g flaxseed
Study: 28327983
Drug: Coil embolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coil embolization with adjunctive techniques (e.g., balloon remodeling)
Study: 21175801
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of 300 mL of 0.1 mol/L hydrochloric acid
Study: 12686509
Drug: Water infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water infusion (control)
Study: 17485422
Drug: Conventional disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional disease-modifying antirheumatic drugs (DMARDs)
Study: 15152293
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nicorandil treatment)
Study: 12466679
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg every 6 h, with one dose on-site each day and others taken home)
Study: 12466679
Drug: Buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.3 mg IM daily)
Study: 2560555
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (glucocorticoid antagonist)
Study: 17545717
Drug: Fosamprenavir/ritonavir 1400/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosamprenavir/ritonavir 1400/200 mg once a day plus TDF 300 mg once a day
Study: 11468730
Drug: Continuous IFNalpha‐n1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IFNalpha‐n1 therapy (group 2)
Study: 11468730
Drug: Standard IFNalpha‐n1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IFNalpha‐n1 therapy (group 3)
Study: 11468730
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy (group 1)
Study: 9875905
Drug: PAFra (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAFra (120 mg iv every 12 hrs over a 4-day period)
Study: 2647818
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with freeze-dried birch-pollen antigens for 18 months, cumulative dose of 280 x 10(6) biologic units
Study: 27670203
Drug: Dexchlorpheniramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexchlorpheniramine plus betamethasone (three daily doses for 7 days)
Study: 27670203
Drug: Desloratadine plus
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine plus prednisolone (single dose followed by two of placebo for 7 days)
Study: 26305866
Drug: Non-aspirin NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin NSAID use
Study: 21640518
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy with chemotherapy (RT-CHT)
Study: 11403243
Drug: Traditional outpatient
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional outpatient therapy (Home group, n = 10)
Study: 3420976
Drug: PDEV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDEV vaccine
Study: 4081704
Drug: HDCV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV vaccine
Study: 8036825
Drug: PDEV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDEV and HDCV vaccines
Study: 30910489
Drug: Nonanimal hyaluronic
Normalized name: nonanal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonanimal hyaluronic acid (NASHA) 1 mL intra-articular injection
Study: 18422164
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal spray < or =400 microg/d
Study: 18422164
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal spray 1 ‐ <3 year
Study: 18422164
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal spray 3 ‐ <5 year
Study: 18422164
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal spray > or =5 year
Study: 9516030
Drug: Acetaminophen 2
Normalized name: acetaminophen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 2 g
Study: 12651647
Drug: Control (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Vitamin C 500 mg)
Study: 11185633
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg plus Telmisartan 120 mg
Study: 8348256
Drug: Ketotifen (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (0.5 mg for children younger than one year and 1 mg for older children)
Study: 24768240
Drug: Baerveldt Glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt Glaucoma Implant (BGI)
Study: 10706930
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy
Study: 332349
Drug: Cyclic combination
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic combination chemotherapy (50 patients)
Study: 332349
Drug: Cyclic combination
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic combination chemotherapy with total‐body irradiation (34 patients)
Study: 332349
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (34 patients)
Study: 15163505
Drug: Monovalent aluminum-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent aluminum-adjuvanted whole virus formulations with 1.9 microg HA per dose
Study: 15163505
Drug: Monovalent aluminum-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent aluminum-adjuvanted whole virus formulations with 3.75 microg HA per dose
Study: 15163505
Drug: Monovalent aluminum-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent aluminum-adjuvanted whole virus formulations with 7.5 microg HA per dose
Study: 15163505
Drug: Split virus
Normalized name: INFLUENZA SPLIT VIRUS '95-'96 VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split virus vaccine (15 microg HA per dose) without aluminum adjuvantation